OpGen

OpGen (NASDAQ: OPGN)

Currency in USD

Last close As at 22/09/2023

USD0.23

▲ −0.01 (−4.17%)

Market capitalisation

USD2m

Overview
Price performance
Financials
Research
Sector insights
Thematics

OpGen is primarily a lab diagnostic manufacturer focused on identifying and treating bacterial infections. It has the technology to detect pathogens and predict resistance. Through the dual platform offering of the AMR Gene Panel and Unyvero, it can provide diagnostic results in hours instead of days.

It currently takes days to test a patient sample to find out if they have an infection, what they are infected with and to which drugs that infection might be susceptible. This can lead to a delay in treatment or the wrong treatment being prescribed. According to the Centers for Disease Control and Prevention, there are over two million cases of drug-resistant bacterial infections every year.

Latest Insights

Healthcare |
Update

14.08.23

OpGen — Cash concerns dampen active Q2

Healthcare |
Flash note

04.08.23

OpGen — FIND collaboration advances to development

Healthcare |
Flash note

21.07.23

OpGen — Feasibility milestone from FIND collaboration

Healthcare |
Update

17.05.23

OpGen — Optimistic start to kick off a promising year

Visit Website

Sector

Healthcare

Equity Analyst

Soo Romanoff

Managing Director - Head of Content, Healthcare

Key Management

Albert Weber

CFO
Oliver Schacht

CEO

Balance Sheet

Forecast net debt (US$m)

N/A

Forecast gearing ratio (%)

N/A

Share Price Performance

Price Performance
%	1M	3M	12M
Actual	12.5	(64.3)	(97.3)
Relative	14.3	(64.0)	(97.7)
52 week high/low	US$8.3/US$0.2

Financials

OpGen is a diagnostics company focused on the identification and treatment of bacterial infections. Its portfolio of molecular diagnostic tests includes the Unyvero platform with five CE-IVD-marked tests and two FDA-cleared cartridges; Ares Genetics’ next-generation antimicrobial resistance (AMR) testing services; the 510(k) cleared Acuitas AMR Gene Panel in bacterial isolates; and ARES Genetics (NGS and bioinformatics platform). Its products are differentiated by a short turnaround time, the detection of a large range of pathogens and AMR profiling. OpGen recently announced a non-exclusive US distribution agreement with Fisher Healthcare and the extension of the FIND collaboration to development stage, both key developments. It reported 23.9% y-o-y top-line growth in Q223, but a short cash runway into September 2023 raises the going concern risk.